An in vitro paradigm to assess potential anti-Aβ antibodies for Alzheimer's disease

Nat Commun. 2018 Jul 11;9(1):2676. doi: 10.1038/s41467-018-05068-w.


Although the amyloid β-protein (Aβ) is believed to play an initiating role in Alzheimer's disease (AD), the molecular characteristics of the key pathogenic Aβ forms are not well understood. As a result, it has proved difficult to identify optimal agents that target disease-relevant forms of Aβ. Here, we combined the use of Aβ-rich aqueous extracts of brain samples from AD patients as a source of human Aβ and live-cell imaging of iPSC-derived human neurons to develop a bioassay capable of quantifying the relative protective effects of multiple anti-Aβ antibodies. We report the characterization of 1C22, an aggregate-preferring murine anti-Aβ antibody, which better protects against forms of Aβ oligomers that are toxic to neurites than do the murine precursors of the clinical immunotherapeutics, bapineuzumab and solanezumab. These results suggest further examination of 1C22 is warranted, and that this bioassay maybe useful as a primary screen to identify yet more potent anti-Aβ therapeutics.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alzheimer Disease / drug therapy
  • Alzheimer Disease / immunology*
  • Alzheimer Disease / metabolism
  • Amyloid beta-Peptides / immunology*
  • Amyloid beta-Peptides / metabolism
  • Animals
  • Antibodies, Monoclonal / immunology*
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized / immunology
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Brain / drug effects
  • Brain / immunology*
  • Brain / metabolism
  • Humans
  • Mice
  • Neurons / drug effects
  • Neurons / immunology
  • Neurons / metabolism


  • Amyloid beta-Peptides
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • solanezumab
  • bapineuzumab